Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma

Launched by INSTITUT CLAUDIUS REGAUD · May 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain medications can help improve the treatment of advanced melanoma, a serious type of skin cancer. Researchers are looking specifically at how a drug that blocks tumor necrosis factor (TNF), called certolizumab or infliximab, might enhance the effects of immune checkpoint inhibitors (ICIs), which are treatments that help the body’s immune system fight cancer. The trial aims to understand how these combined treatments can boost the immune response against melanoma and whether they can lead to better outcomes for patients.

To be eligible for this trial, participants must be enrolled in one of two specific clinical trials: TICIMEL or MELANFalpha. There are no restrictions based on age or gender, but participants should have advanced melanoma. Those who join can expect to receive either the combination of TNF inhibitors with ICIs or just the ICIs alone, and the research team will closely monitor how their bodies respond. This study is important because it could help identify the best treatment strategies for melanoma and improve the overall understanding of how to enhance immune responses in cancer therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion in TICIMEL clinical trial (NCT03293784),
• • Inclusion in MELANFα trial (NCT03348891)
• Exclusion Criteria:
• • NA